South Korea Viscosupplementation Market Size, Share, and COVID-19 Impact Analysis, By Product (Single Injection, Three Injection, and Five Injection), By End-use (Hospitals and Orthopedic Clinics/ASCs), and South Korea Viscosupplementation Market Insights, Industry Trend, Forecasts to 2035.

South Korea Viscosupplementation Market Insights Forecasts to 2035

• The South Korea Viscosupplementation Market Size Was Estimated at USD 69.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 11.85% from 2025 to 2035
• The South Korea Viscosupplementation Market Size is Expected to Reach USD 236.6 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Viscosupplementation Market Size is anticipated to reach USD 236.6 Million by 2035, growing at a CAGR of 11.85% from 2025 to 2035. The goal of viscosupplementation is to improve knee function and reduce joint pain. The need for viscosupplementation is largely being driven by the rising prevalence of osteoarthritis (OA). The main cause of long-term incapacity is osteoarthritis, a chronic degenerative joint disease.

Market Overview

A medical technique called viscosupplementation involves injecting hyaluronic acid into a joint, mainly to alleviate the pain and stiffness associated with osteoarthritis. By restoring synovial fluid, it seeks to enhance joint lubrication and cushioning, providing a non-surgical alternative for osteoarthritis treatment. Viscosupplementation can greatly lessen osteoarthritis-related joint discomfort, enhancing function and mobility. Viscosupplementation is a less intrusive method that requires less recovery time than surgical operations. With rising healthcare costs and an aging population, emerging economies are predicted to see substantial growth in the viscosupplementation industry. Viscosupplementation is mainly used to treat osteoarthritis in the knee, there is rising interest in using it to other joints, like the shoulder. Public awareness campaigns on osteoarthritis and the advantages of viscosupplementation as a therapy option, particularly for knee discomfort, are being launched by governments. To increase access to viscosupplementation and other minimally invasive therapies, governments are spending money on healthcare infrastructure, such as physical therapy hubs and ambulatory surgical centers (ASCs).

Report Coverage

This research report categorizes the market for South Korea viscosupplementation market based on various segments and regions forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea viscosupplementation market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea viscosupplementation market.

Driving Factors

The rising prevalence of osteoarthritis especially among aging and sedentary populations, increasing demand for non surgical treatments, and technological advancements in hyaluronic acid formulations and delivery systems. Sports related joint injuries, favorable reimbursement policies, expanding healthcare infrastructure, and growing awareness among patients and clinicians about the benefits of minimally invasive joint therapies.

Restraining Factors

High costs and limited insurance coverage reduce patient affordability, particularly where reimbursement is lacking. Alternative treatments like NSAIDs, physical therapy, and corticosteroid injections often offer cheaper, more familiar options. Additionally, inconsistent clinical evidence and ongoing debates about long-term efficacy, along with potential side effects

Market Segmentation

The South Korea viscosupplementation market share is classified into product and end-use.

• The single injection segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea viscosupplementation market is segmented by product into single injection, three injection, and five injections. Among these, the single injection segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. Single injection reduced treatment time, and lower risk of complications compared to multiple injections. Increasing patient preference for minimally invasive options and improved formulations offering longer-lasting relief contribute to its growing adoption

• The hospitals segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea viscosupplementation market is segmented by end-use into hospitals and orthopedic clinics/ASCs. Among these, the hospitals segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segmental growth due to better access to advanced viscosupplementation therapies, skilled professionals, and comprehensive diagnostic facilities. Patients prefer hospitals for complex joint treatments, and the rising prevalence of osteoarthritis is increasing hospital visits

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea viscosupplementation market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• LG Chem Ltd. 
• Hanmi Pharmaceutical
• Daewoong Pharmaceutical
• Chong Kun Dang
• Hanmi Fine Chemical
• Janssen Korea
• Samsung Biologics
• SK Biopharmaceuticals
• Celltrion
• Medytox
• Daewoong Bio
• Others

Recent Developments:

• In November 2024, GlobalData’s Market Model methodology determined that the leading player in the viscosupplementation market in South Korea was Sanofi followed by Seikagaku, Ferring Pharmaceuticals, Zimmer Biomet, Fidia farmaceutici and Anika Therapeutics.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea viscosupplementation market based on the below-mentioned segments:

South Korea Viscosupplementation Market, By Product

• Single Injection
• Three Injection
• Five Injection

South Korea Viscosupplementation Market, By End-use

• Hospitals
• Orthopedic Clinics/ASCs